BIOMAT Database Logo BIOMAT Database Logo

Inhibitory activity of 9-phenylcyclohepta[d]pyrimidinedione derivatives against different strains of HIV-1 as non-nucleoside reverse transcriptase inhibitors. 2011

Yang Huang, and Xiaowei Wang, and Xiaoling Yu, and Lin Yuan, and Ying Guo, and Weisi Xu, and Tiejun Liu, and Junyi Liu, and Yiming Shao, and Liying Ma
State Key Laboratory for Infection Disease Prevention and Control, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (CDC), China. yshao@bbn.cn

BACKGROUND The non-nucleoside reverse transcriptase inhibitor (NNRTI), as a major component of the highly active antiretroviral therapy (HAART) to HIV-1 (human immunodeficiency virus type 1) infected patients, required the development of new NNRTIs with improved resistance profile and decreased toxicity. Therefore, a series of novel compounds, 9-phenylcyclohepta[d]pyrimidinedione derivatives (PCPs), were designed based on the chemical structure of TNK-651, to detect anti-HIV-1 activity. RESULTS 1-[(benzyloxy)methyl]-9-phenyl-cyclohepta[d] pyrimidinedione (BmPCP) among four PCPs has antiviral activity on laboratory-adapted HIV strains (HIV-1 SF33). The results showed 50% inhibition concentrations (IC50s) of BmPCP were 0.34 μM, 1.72 μM and 1.96 μM on TZM-bl, peripheral blood mononuclear cells (PBMCs) and MT4, respectively. It was also effective against infection by the predominant HIV-1 isolates in China, with IC50s at low μM levels. Its selectivity index (SI) ranged from 67 to 266 in different cells. The results of time-of-addition assay demonstrated that BmPCP inhibited HIV-1 infection by targeting the post entry of the HIV-1 replication cycle. For inhibition of HIV-1 reverse transcriptase activity, the IC50 values of BmPCP and NVP were 1.51 and 3.67 μM, respectively. CONCLUSIONS BmPCP with a novel structure acts as a NNRTI to inhibit HIV-1 replication and can serve as a lead compound for further development of new anti-HIV-1 drugs.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003508 Cycloheptanes Seven-carbon cycloparaffin cycloheptane (the structural formula (CH2)7) and its derivatives.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Yang Huang, and Xiaowei Wang, and Xiaoling Yu, and Lin Yuan, and Ying Guo, and Weisi Xu, and Tiejun Liu, and Junyi Liu, and Yiming Shao, and Liying Ma
Discovery of Phenylaminopyridine Derivatives as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
August 2012, ACS medicinal chemistry letters,
Yang Huang, and Xiaowei Wang, and Xiaoling Yu, and Lin Yuan, and Ying Guo, and Weisi Xu, and Tiejun Liu, and Junyi Liu, and Yiming Shao, and Liying Ma
Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
September 2009, Bioorganic & medicinal chemistry letters,
Yang Huang, and Xiaowei Wang, and Xiaoling Yu, and Lin Yuan, and Ying Guo, and Weisi Xu, and Tiejun Liu, and Junyi Liu, and Yiming Shao, and Liying Ma
Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.
June 2012, ACS medicinal chemistry letters,
Yang Huang, and Xiaowei Wang, and Xiaoling Yu, and Lin Yuan, and Ying Guo, and Weisi Xu, and Tiejun Liu, and Junyi Liu, and Yiming Shao, and Liying Ma
Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
July 2010, Journal of medicinal chemistry,
Yang Huang, and Xiaowei Wang, and Xiaoling Yu, and Lin Yuan, and Ying Guo, and Weisi Xu, and Tiejun Liu, and Junyi Liu, and Yiming Shao, and Liying Ma
Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
February 2008, Bioorganic & medicinal chemistry letters,
Yang Huang, and Xiaowei Wang, and Xiaoling Yu, and Lin Yuan, and Ying Guo, and Weisi Xu, and Tiejun Liu, and Junyi Liu, and Yiming Shao, and Liying Ma
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
February 2004, Journal of medicinal chemistry,
Yang Huang, and Xiaowei Wang, and Xiaoling Yu, and Lin Yuan, and Ying Guo, and Weisi Xu, and Tiejun Liu, and Junyi Liu, and Yiming Shao, and Liying Ma
Synthesis of novel uracil non-nucleoside derivatives as potential reverse transcriptase inhibitors of HIV-1.
November 2009, Archiv der Pharmazie,
Yang Huang, and Xiaowei Wang, and Xiaoling Yu, and Lin Yuan, and Ying Guo, and Weisi Xu, and Tiejun Liu, and Junyi Liu, and Yiming Shao, and Liying Ma
Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.
August 1999, AIDS (London, England),
Yang Huang, and Xiaowei Wang, and Xiaoling Yu, and Lin Yuan, and Ying Guo, and Weisi Xu, and Tiejun Liu, and Junyi Liu, and Yiming Shao, and Liying Ma
Identification of Boronate-Containing Diarylpyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.
November 2022, Molecules (Basel, Switzerland),
Yang Huang, and Xiaowei Wang, and Xiaoling Yu, and Lin Yuan, and Ying Guo, and Weisi Xu, and Tiejun Liu, and Junyi Liu, and Yiming Shao, and Liying Ma
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
February 2006, Current opinion in investigational drugs (London, England : 2000),
Copied contents to your clipboard!